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PURPOSE. Chemokines play a role in the progression and metastatic spread of both cutaneous
and uveal melanomas. The aim of this study was to examine the prognostic value of
expression of chemokine receptors CCR7, CXCR4, and CCR10 in conjunctival melanocytic
lesions.
METHODS. In total, 44 conjunctival nevi, 21 cases of primary acquired melanosis (PAM) with
atypia and 35 conjunctival melanomas, were included. After immunohistochemical staining
for CCR7, CXCR4, and CCR10 the immunoreactive score (IRS) was determined. The findings
were correlated for association with melanoma and development of metastasis. For
mechanistic evaluation, we used a mouse melanoma metastasis model using two human
conjunctival melanoma cell lines, CM2005.1 and CRMM1.
RESULTS. All tested chemokines showed a significantly higher expression in conjunctival
melanoma than conjunctival nevi. There was a statistically significant difference between the
IRS in nevi and PAM with atypia for nuclear IRS in CCR10 (P ¼ 0.03) and both nuclear and
cytoplasmic IRS in CXCR4 (P < 0.01 and P ¼ 0.03, respectively); this was also true evaluating
the groups PAM with atypia and melanoma all together (P < 0.01). Furthermore, a trend for
lower IRS was seen in cases of melanoma without metastasis, with a suggestive pattern of a
higher IRS in cases that did develop metastases, supported for CXCR4 using the mouse
melanoma metastasis model.
CONCLUSIONS. Expression of specific chemokines changes during the progression and
metastatic spread of conjunctival melanocytic lesions. Differential chemokine profiles may
hold prognostic value for patients with conjunctival melanomas and might be considered as a
therapeutic target.
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Conjunctival melanomas comprise 5% of all ocular melano-mas1 and show an increase in incidence. The majority of
these melanomas is derived from primary-acquired melanosis
(55%), while 25% arises de novo, and a minority of the
conjunctival melanomas derives from nevi.2 Conjunctival
melanoma is associated with morbidity due to the frequent
recurrences, with a 10-year mortality rate due to metastasis up
to 30% to 39% in 10 years.2,3 Once metastasized, there are only
limited treatment options. This emphasizes the need for
identification of biomarkers for early detection, prediction,
and as potential treatment targets of lesions with more
aggressive behavior. Many attempts have been made to predict
the metastatic behavior of a conjunctival melanocytic lesion
searching for prognostic parameters, including clinical and
histopathologic parameters4 and molecular changes, such as
BRAF and TERT promoter mutations.5 Nevertheless, the exact
mechanism of metastasis has not been elucidated yet. Chemo-
kines are thought to be involved in tumor proliferation,
invasion, and angioinvasiveness,6–8 and to play an important
role in the metastatic process in different types of cancer,9
including cutaneous and uveal melanoma.9–12 Furthermore,
chemokines play a role in inflammatory responses,13,14 which
might be involved in tumor progression.14,15 Chemokine
receptors are cytokine receptor-like G-linked proteins on the
cell surface and are classified into four different groups,
depending on the position of the cysteine residues.10,11,14 It
is suspected that tumor cells that express specific chemokine
receptors tend to migrate toward the specific organ that
produces the complementary ligand.7,10,14,16,17 In this meta-
static process, a role of a chemokine gradient is suggested6,18 as
well as an interaction between different chemokines and their
receptors, matrix metalloproteinases, VEGF, and EGFR.7 In
melanocytic tumors, CXCR4, with its ligand CXCL12 (also
known as stromal cell-derived factor 1 [SDF-1]7,17), CCR7 with
ligands CCL19 and CCL21,9,18 and CCR10 with ligand CCL27
are thought to play a role in the metastatic spread.18 So far little
is known regarding chemokine receptor expression in con-
junctival melanoma.3
The aim of this study was to examine the prognostic value of
tumor cell expression of chemokine receptors CCR7, CXCR4,
Copyright 2019 The Authors
iovs.arvojournals.org j ISSN: 1552-5783 2950
This work is licensed under a Creative Commons Attribution 4.0 International License.
Downloaded from iovs.arvojournals.org on 08/05/2019
and CCR10 in conjunctival melanocytic lesions, with emphasis
on chemokines predicting progression toward melanoma and
melanoma metastasis, in order to provide a basis for more
precise selection of patients in need of follow-up.
MATERIALS AND METHODS
Tissue Samples
Formalin-fixed paraffin-embedded samples of 44 conjunctival
nevi, 21 cases of PAM with moderate to severe atypia and 35
conjunctival melanomas, were collected at the Erasmus MC,
Department of Pathology, The Netherlands, between 1987 and
2013. All relevant slides were revised by an ophthalmic
pathologist (RVE). For every case of PAM with atypia,
information about the presence of melanoma at some point
in the patients’ history was collected from the patient records
(in The Rotterdam Eye Hospital and Erasmus MC, Rotterdam,
The Netherlands) and the nationwide pathology network and
registry system (PALGA). In a similar manner information about
melanoma metastasis was collected. Medical Ethics Committee
approval was obtained (Medisch Ethische Toetsingscommissie
reference 67865). Patient characteristics are displayed in Table
1. Depending on the size of the lesion one to three
representative 5-mm cores were selected from the relevant
blocks of the formalin-fixed paraffin embedded material, in
order to produce a tissue microarray (TMA).12
Immunohistochemistry (IHC) CCR7, CXCR4, and
CCR10
The samples were stained using an automated IHC staining
system (Ventana Benchmark ULTRA; Ventana Medical System
Inc., Tucson, AZ, USA), using alkaline phosphatase method for
all antibodies, as described by Van den Bosch et al.12 In short,
after deparaffinization and heat-induced antigen retrieval
(CCR7, CCR10) or protease treatment (CXCR4), the tissue
sections were incubated with primary mouse antibody against
CCR7 for 64 minutes at 978C (clone 150503, 1:5000; R&D
Systems, Minneapolis, MN, USA), CXCR4 for 36 minutes at
978C (clone 44716, 1:128,000; R&D Systems), and primary
rabbit antibody CCR10 for 64 minutes at 978C (ab30718, 1:400;
Abcam, Cambridge, UK). The tissue was counterstained with
hematoxylin II followed by bluing reagent, according to the
manufacturer’s instructions. Liver, tonsil, intestinal, and breast
tissue was used as a control.
For every TMA core an immunoreactive score (IRS) was
determined. We first determined the intensity of the staining
(absent, mild, moderate, and intense, scored as 0, 1, 2, or 3,
respectively). For CCR10 and CXCR4, the intensity of the
nuclear and the cytoplasmic staining was determined separately;
for CCR7 only cytoplasmic staining was observed (Fig. 1). Next,
the percentage of stained cells that showed the predominant
intensity, was determined; no positive cells were scored as 0%
and less than 10%, 10% to 50%, 51% to 80%, and more than 80%
were scored as 1, 2, 3, or 4, respectively. Then, IRS was
calculated by multiplying the score for percentage of stained
cells with the score for the intensity of the staining. The IHC
staining was evaluated by an ophthalmic pathologist (RVE), a
senior pathology resident (JIP), and medical student (KBA)
trained in the assessment of conjunctival lesions and IRS
evaluation, using light microscopy; in case of a difference
consensus was reached by joint re-evaluation. It was not
possible to determine the IRS for all chemokines in every case,
either due to detachment of the core during the staining
procedure or due to lack of material. For the 32 cases where
multiple cores per chemokine staining were available for review,
the highest IRS for each case was used for further analysis. No
age-related differences in staining intensity were observed.
Cell Lines
To validate our data, we used two conjunctival melanoma (CM)
cell lines, CRMM-1 and CM2005.1 in an in vivo mouse metastasis
model, as described by De Waard et al.19 Human CM cell line
CRMM1 was established by Gordon Nareyeck (Essen, Germany;
kindly provided by Michele Madigan, Sydney, Australia).
CM2005.1 was established by Sander Keijser (LUMC, Leiden,
The Netherlands).20,21 In short, the cell lines of CRMM-1 and
CM2005.1 were separately administered to mice by injecting the
cells into the nasal subconjunctival space. These mice
developed local malignant melanocytic tumors, as confirmed
by histopathology, but no metastases. The local tumor tissues
were harvested and culture passages were produced. These
passages were then separately administered to other mice. In
addition to local tumor growth, those latter mice did develop
metastases. The tissue of the orbital exenterations as well as the
tissue of the metastasis was examined by light microscopy. All
tissues were stained with CCR10, CCR7, and CXCR4 antibodies
and the IRS was determined as described before.
Statistical Analysis
The Wilcoxon rank sum test was used to determine whether
there was a statistical difference in expression of the different
chemokines between the different melanocytic lesions (nevi
compared with PAM with atypia, nevi versus melanoma, PAM
with atypia with versus without occurrence of melanoma,
TABLE 1. Patient Characteristics for Nevi, PAM With Atypia, and
Melanoma, Respectively
Sex M/F
Mean Age
at Time of
Diagnosis (y)
Mean
Follow-up (y)
Nevi 20 (45%)/24 (55%) 41 (6–84) 0 (0–0)
PAM with atypia 12 (57%)/9 (43%) 63 (33–86) 5.2 (0–18.5)
Melanoma 25 (71%)/10 (29%) 64 (41–87) 4.8 (0–21.4)
FIGURE 1. Melanoma, hematoxylin and eosin staining (A, magnification 310), immunohistohemical chemokine expression of CCR7 (B, IRS 12,
magnification 310), CXCR4 (C, nuclear IRS 12, cytoplasmic IRS 8; magnification 310), and CCR10 (D, nuclear IRS12, cytoplasmic IRS 8;
magnification 350).
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melanoma with versus without development of metastasis and
comparison of nevi versus the not benign lesions [precursor
and melanoma lesions all together]). A P < 0.05 was
considered significant.
RESULTS
Immunohistochemistry
Nevi Versus PAM With Atypia. The IRS in nevi could be
determined for CCR7 in 32 cases (72%) and for CXCR4 and
CCR10 in respectively 39 (89%) and 33 cases (75%). In the PAM
with atypia IRS could be determined for CCR7 in 20 cases
(95%), CXCR4 in 15 cases (71%), and CCR10 in 11 cases (52%).
The IRS pattern of PAM with atypia showed a different
chemokine receptor expression pattern when compared with
the nevi group, with a nuclear IRS less than 4 only observed in
nevi for both CCR10 and CXCR4. The difference between nevi
and PAM with atypia was significant for nuclear IRS in CCR10
(P¼0.03) and both cytoplasmic and nuclear IRS in CXCR4 (P¼
0.03 and P < 0.01 respectively; Table 2). CCR7 did not prove to
be differentially expressed.
Nevi Versus Melanoma. For the melanoma IRS could be
determined for both CCR7 and CXCR4 in 34 cases (97%) and
for CCR10 in 33 cases (94%). For all tested chemokines, in
general a high IRS was more frequently found in the melanoma
group. For CCR7 medium to low IRS (IRS < 8) was only seen in
nevi and not in the melanoma group (Fig. 2), with a significant
difference in IRS score (P ¼ 0.02; Table 2). This difference in
both cytoplasmic and nuclear IRS also showed statistical
significance for CXCR4 and CCR10 (maximum P ¼ 0.01;
Table 2).
PAM With Atypia and Association With Melanoma.
Eleven (52%) of the cases of PAM with atypia were associated
with melanoma. IRS could be determined in eleven (100%),
eight (73%), and five (45%) cases for CCR7, CXCR4, and
CCR10, respectively, with IRS determined for cases without
melanoma association in nine (90%), seven (70%), and five
(50%) cases for CCR7, CXCR4, and CCR10, respectively. Low to
medium IRS (IRS < 9) for nuclear expression in CXCR4 was
only found in the precursor lesion without melanoma
association; strikingly the opposite was seen for cytoplasmic
IRS for CXCR4 with more frequently a low IRS in cases that
were associated with melanoma. For CCR10 only a relatively
high IRS (IRS > 8) was seen for nuclear expression in cases
without an association with melanoma, with a tendency of an
opposite effect in the cytoplasmic IRS for CCR10 (see also Fig.
3). For CCR7 a medium to low IRS (IRS < 8) was only seen in
PAM with atypia without melanoma association. However,
none of these findings proved to be statistically significant
(Table 2).
Melanoma and Development of Metastasis. IRS could
be determined for all chemokines in all the metastasized
melanoma cases (n ¼ 5) and for 29 (97%), 28 (93%), and 29
(97%) nonmetastasized melanomas in CCR7, CCR10, and
CXCR4, respectively. IRS 0 was only seen in cases of melanoma
TABLE 2. P Values of the Chemokine Receptor Expression (CCR7, CCR10, CXCR4). When Comparing the Different Subgroups (Conjunctival Nevi,
Primary Acquired Melanosis With Atypia [PAMþ], and [Metastasized] Conjunctival Melanoma)
CCR7
CCR10 CXCR4
Cytoplasm Nuclear Cytoplasm Nuclear
Nevi versus PAMþ 0.97 0.46 0.03 0.03 <0.01
Nevi versus melanoma 0.02 <0.01 0.01 <0.01 <0.01
PAMþ versus melanoma 0.02 0.046 0.86 0.84 0.06
Nevi versus (pre-)malignant lesions 0.10 <0.01 <0.01 <0.01 <0.01
Melanoma associated PAMþ versus not melanoma associated PAMþ 1 0.52 0.92 0.51 0.15
Metastasized melanoma versus non metastasized melanoma 0.12 0.82 0.59 0.44 0.38
Bold values indicate statistical significance, P < 0.05.
FIGURE 2. Boxplots IRS chemokine receptor expression in conjunctival nevi and melanoma.
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without metastasis for chemokine CXCR4 and CCR10 expres-
sion (both nuclear and cytoplasmic expression), with a
suggestive pattern of high IRS in cases that did develop
metastases, as was seen for CXCR4 (Fig. 4). Yet, none of these
findings proved to be statistically significant. Next, we tested if
we could find a differential expression pattern between the
primary melanoma and the metastasized lesion, because of the
theory that melanoma with high chemokine expression would
be attracted to the target organ. Given the results for skin
melanoma,22 one might expect a higher chemokine expression
in the metastatic lesion. For none of the tested chemokines,
either cytoplasmic or nuclear expression, a differential pattern
was found between the chemokine expression in the primary
tumor and the corresponding metastatic lesion (data not
shown). In light of this discrepancy between the results for
skin melanoma and conjunctival melanoma we used a mouse
model to provide further insight in the mechanism of
metastatic spread of conjunctival melanoma.
We also evaluated whether the above-mentioned findings
for CCR10 and CXCR4 would change by taking into account
only the highest IRS, without distinction between cytoplasmic
or nuclear IRS. No new insights were gained.
Cell Lines
After the first administration, both conjunctival melanoma cell
lines CRMM-1 and CM2005.1 gave rise to a local subconjunc-
tival melanoma, but none of the mice developed metastases.
After culture passage and administration of these passages to
new mice, both cell lines (hereafter mentioned as passaged
tumor) gave rise to metastasis to the lungs. For CXCR4 there
was an increased expression in the passaged tumor and the
metastasized lesion relative to the primary inoculated tumor
(Figs. 5, 6). We observed no further increase in chemokine
receptor expression in the metastatic lesion compared with
the passaged tumor. Neither of the two cell lines showed a
difference in expression for CCR10 or CCR7 comparing the
primary tumor, the passaged tumor, and the metastatic lesion
(Figs. 5, 6).
FIGURE 3. Boxplots IRS chemokine receptor expression in primary acquired melanosis with atypia (PAMþ) associated with conjunctival melanoma
(PAMþ/melþ) and PAMþ not associated with melanoma (PAMþ/mel).
FIGURE 4. Boxplots IRS chemokine receptor expression in conjunctival melanoma with metastasis (mel/Mþ) and melanoma without metastasis
(mel/M).
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FIGURE 5. Chemokine receptor expression in the mouse metastasis model using conjunctival melanoma cell line CM2005 (upper and middle
figures being the primary tumour [primary tumor and passaged tumor (P#3), respectively]) and the lower figures being the metastatic lesion (lung
P#4), with the figures on the left side depicting CCR7 expression, the middle figures depicting CCR10 expression and on the right side figures
depicting CXCR4 expression.
FIGURE 6. Chemokine receptor expression in the mouse metastasis model using conjunctival melanoma cell line CRMM1 (upper and middle
figures being the primary tumor [primary tumor and passaged tumor (P#3), respectively]) and the lower figures being the metastatic lesion (lung
P#4), with the figures on the left side depicting CCR7 expression, the middle figures depicting CCR10 expression and on the right side figures
depicting CXCR4 expression.
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Chemokine Expression in Human Primary
Melanoma and Related Metastatic Lesions
Chemokine expression was analyzed for all described chemo-
kines in the tissue of four patients, whose primary lesion as
well as the corresponding metastatic lesion were available for
analysis. The IRS was determined as described in the primary
lesion and the corresponding metastasis subsequently. No
specific pattern was found evaluating the IRS in the primary
lesion and the corresponding metastatic lesion.
DISCUSSION
CCR10, CCR7, and CXCR4 are known to play an important role
in the tumorigenesis of cutaneous melanomas.23 Because of the
resemblance of skin melanoma and conjunctival melanoma in
many ways24 we aimed to evaluate the prognostic value of
chemokine expression in conjunctival melanocytic lesions.
In this study, we found significant differences in chemokine
profile in nevi versus primary acquired melanosis with atypia
and melanoma, with a low chemokine level for all tested
chemokines in the nevus group. This was also true when
evaluating the chemokine analysis in the nevi versus the
premalignant lesions and the malignant lesions combined.
CXCR4 is known to be highly involved in the carcinogenesis
of various tumors,9 with CXCR4/CXCL12 (SDF-1) pathway
described to be involved in skin melanoma,17 colorectal
cancer,25 and uveal melanoma,26,27 among others. Binding of
CXCR4 to CXCL12 induces the phosphoinositide 3-kinase
(PI3K)-Akt and mitogen-activated protein kinase (MAPK)
pathways9,14,26 resulting in tumor cell survival and migration.9
PI3K-Akt activation combined with the MEK pathway also
induces matrix metalloproteinase expression giving rise to
degradation of the extracellular matrix, while the PI3K-
pathway combined with extracellular signal-regulated kinases
1/2 (ERK1/2) results in cell invasiveness. Furthermore, the
production of proangiogenic factors, including VEGF, in
response to CXCL12 contributes to the carcinogenic effect.9
Petit et al.28 suggest a vicious circle with hypoxia induced by
the tumor resulting in upregulation of VEGF, with not only
tumor cells and tumor stroma cells, but also endothelial
progenitor cells expressing and secreting SDF1, the expression
of SDF-1 directly being linked to the magnitude of the hypoxia.
These pathways may also explain our results concerning both
cytoplasmic and nuclear IRS for CXCR4 in nevi versus
(pre-)malignant lesions. Different results were found in the
study of chemokine receptor expression in uveal melanoma by
Van den Bosch et al.,12 which might be explained by the
difference in location and well-known involvement of other
(epi)genetic factors.5
The CCR7/CCL21 axis is also involved in the tumor
progression via the aforementioned pathways,9 with a high
expression of CCR7 associated with an adverse prognosis in
both cutaneous and uveal melanoma.12 Therefore, one might
presume that the lower the expression of CCR7 the more
unlikely the cells are to migrate and invade, explaining our
findings of low IRS in nevi, in contrast to the lesions with frank
malignant behavior (i.e., melanoma). Furthermore, this path-
way is known to be involved in attracting specific inflamma-
tory cells toward the tumor in vicinity of CCL21 of that tumor,
resulting in inhibition of the melanoma.13 Because all but one
of the melanoma cases in this study (n ¼ 34) did have a
lymphocytic infiltrate associated with the tumor, one might
expect some influence of this infiltrate on the tumor behavior.
One might assume that higher expression of CCR7 of the
tumor leads to higher levels of CCL21 in the environment of
the tumor, thereby influencing the behavior of the tumor by
the lymphocytic infiltrate, leading to a more favorable course.
We were not able to confirm this assumption with the results
of our study, may be because of the influence of high
(co-)expression of CXCR4, which is also suggested to play a
role in tumorigenesis via lymphocyte infiltration.14,15
Overexpression of CCR10 is associated with a worse
prognosis, as described in cutaneous melanoma.17 Adverse
behavior of melanocytic lesions with CCR10 overexpression
was also found in our study.
Although clear differences were observed between the
benign and the (pre-)malignant groups, no statistical differences
were found when comparing PAM with atypia associated with
melanoma versus PAM with atypia without association with
melanoma. The relatively small sample size of the group PAM
with atypia might explain this lack in statistical significance. On
the other hand, PAM with atypia is interpreted by some as
melanoma in situ29 and only cases showing moderate to severe
atypia comparable to a minimal conjunctival melanocytic
intraepithelial neoplasia (C-MIN) score of 5 have been selected
for this study. According to this newly proposed grading system
a C-MIN score of 5 and higher can be interpreted as melanoma in
situ.29 In view of this, it may not be surprising that the
chemokine expression between melanoma in situ and melano-
ma shows no statistically significant differences.
Another aim of this study was to evaluate whether it would
be possible to make a prediction about the metastatic potential
of a malignant lesion on the basis of chemokine expression. In
this study we frequently found a high IRS for CXCR4 in lesions
that did metastasize, congruent with findings in other studies
where CXCR4 overexpression is said to enhance invasive
capacity.7,11,25,30 Of particular interest is the very low IRS of
CXCR4 that was seen in the cases that did not develop
metastasis. This is in line with the suggestion of Ehtesham et
al.30 that silencing of CXCR4 could inhibit the metastatic
potential of the tumor cells and the statement of CXCR4 being
very important in metastatic capacity as was also confirmed in
other studies.7,30 This also explains our finding of a higher
metastatic potential of melanomas with a higher CXCR4
expression compared with melanomas with less expression
of CXCR4. Although this is a suggestive pattern, in our cohort
no statistical significance could be found comparing the
chemokine expression in the melanomas that proved to have
metastatic capacity and the melanomas without metastasis,
probably because of the small group size of the metastasized
group. Given these results, in combination with the results
described by others in skin melanoma,22 we tested if a
differential chemokine receptor expression pattern could be
observed in a mouse metastasis model for conjunctival
melanoma. In this model, we show that at primary inoculation
the tumors that developed from the human conjunctival
melanoma cell lines have low expression of CXCR4 and no
metastasis were seen. In contrast, after passaging and
inoculation into new mice, melanomas with high CXCR4
expression developed metastases to the lungs. This is in
concordance with the known beneficial environment in the
lungs for CXCR4 expressing melanoma cells.23 Such findings
were not seen for CCR7 and CCR10 and appeared to be limited
to CXCR4 expression, where both nuclear and cytoplasmic
expression were increased in the passaged tumor and the
metastatic lesion. The increase in nuclear expression is
interesting, because CXCR4 is a membranous protein.
Increased nuclear expression of CXCR4 has been explained
by either a mutation in CXCR4, leading to misfolding and
mistranslocation of the protein or elevated levels of SDF-1
causing internalization of CXCR4, resulting in nuclear CXCR4
expression, as suggested by Wang et al.25 The enhanced
metastatic capacity caused by increased CXCR4 expression,
and the absence of similar results for CCR10 and CCR7, might
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be explained by a combined pathway with involvement of a
mutation (either in SDF-1 or CXCR4) in (synergistic) combina-
tion with an alternative pathway with CXCR4 involvement.
This hypothesis has yet to be explored.
Consistent with the pattern observed in the mouse model,
in human tissue the chemokine expression in the primary
tumor when compared with the corresponding metastatic
lesion did not show further upregulation in the metastatic
lesion versus the primary tumor. This finding might be due to
the small sample size. Another explanation might be that
evaluation of protein expression by (only) immunohistochem-
istry is not sensitive enough and that alterations on mRNA level
have to be evaluated as well to show further upregulation of
chemokine receptor expression after metastasis. Discrepancies
between chemokine expression by immunohistochemical
evaluation and mRNA level have been reported.18,31 Last, and
most important, increased chemokine receptor expression in
the primary tumor may be sufficient for homing to the
metastatic site with no need for further upregulation upon
arrival.
Although we were not able to find a statistically significant
predictive chemokine expression pattern in the tumor cells
that could discriminate the melanoma associated PAM with
atypia from the PAM with atypia not associated with
melanoma progression, we did find a significant difference
when comparing the PAM with atypia and melanoma with the
nevi, suggesting a clear role for CCR7, CCR10, and CXCR4
overexpression in the melanoma tumorigenesis. The mouse
conjunctival melanoma metastasis model showed upregu-
lation of CXCR4 to be related to metastatic potential of two
human conjunctival melanoma cell lines. This implies that
suppression of the expression of those chemokine receptors,
for example by means of medication (CCR7, CCR10, and
CXCR4 antagonists), might either prevent or possibly reduce
the tumor progression, by influencing the tumor environ-
ment, angiogenesis, and proliferation capacity of the tumor
cells, and might prevent recurrences or metastasis. Of course,
this has to be examined in further studies and caution is
required, given the results of Wendt et al.32 suggesting that
interruption of the CXCR4-CXCL12 axis can favor metastatic
disease.
CONCLUSIONS
Our results confirm the involvement of CCR7, CCR10, and
CXCR4 in neoplastic melanocyte biology of the conjunctiva.
Especially CCR10 and CXCR4 changes during the progression
and metastatic spread of conjunctival melanocytic lesions.
Differential chemokine profile may hold prognostic value for
patients with conjunctival melanomas and might be considered
as a therapeutic target.
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